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Summary
Bone is constantly resorbed and formed throughout
life by coordinated actions of osteoclasts and osteo-
blasts. Here we show that Smurf1, a HECT domain
ubiquitin ligase, has a specific physiological role in
suppressing the osteogenic activity of osteoblasts.
Smurf1-deficient mice are born normal but exhibit an
age-dependent increase of bone mass. The cause of
this increase can be traced to enhanced activities of
osteoblasts, which become sensitized to bone mor-
phogenesis protein (BMP) in the absence of Smurf1.
However, loss of Smurf1 does not affect the canonical
Smad-mediated intracellular TGF or BMP signaling;
instead, it leads to accumulation of phosphorylated
MEKK2 and activation of the downstream JNK signal-
ing cascade. We demonstrate that Smurf1 physically
interacts with MEKK2 and promotes the ubiquitina-
tion and turnover of MEKK2. These results indicate
that Smurf1 negatively regulates osteoblast activity
and response to BMP through controlling MEKK2
degradation.
Introduction
From late stages of embryonic development and con-
tinuing during adult life, bone is constantly resorbed
and formed by remodeling at microscopic sites
throughout the skeleton (Karsenty and Wagner, 2002).
Bone resorption is carried out by haematopoietically
derived osteoclasts, whereas formation of the mineral-
ized bone is the function of mesenchyme-derived os-
teoblasts. Concerted action by these two opposing
types of cells is required for maintaining proper bone
mass and integrity in the adult skeleton.
Bone-forming osteoblasts first arise during embry-
onic development after patterning of a given skeletal
element is complete (Karsenty and Wagner, 2002).
Commitment of mesenchymal progenitors to the osteo-*Correspondence: yingz@helix.nih.govblastic lineage requires sequential actions of Runx2
and Osterix, two osteoblast-specific transcription
factors. Once differentiated, osteoblasts begin to syn-
thesize alkaline phosphatase, type I collagen, osteocal-
cin, and bone sialoprotein and deposit them to bone
extracellular matrix (ECM). Recent genetic studies in
mice indicate that maintaining the differentiated osteo-
blast phenotype and bone-forming function not only re-
quires the input of the commitment factors Runx2 and
Osterix, but other transcription factors such as JunB
and Fra-1 of the AP-1 family (Kenner et al., 2004; Eferl
et al., 2004) and ATF4 of the CREB/ATF family (Yang et
al., 2004) also play an indispensable role. These pro-
teins often recognize distinct cis-acting elements in os-
teoblast-specific promoters and act in conjunction with
other transcription factors to activate the expression of
bone ECM components. For example, Runx2, ATF4,
and AP-1 binding sites are found in the promoter of
osteocalcin; all of these contribute in transcriptional ac-
tivation of osteocalcin (Ducy and Karsenty, 1995; Yang
et al., 2004).
In addition to the cell-autonomous controls by tran-
scription factors, osteoblast differentiation and its
bone-forming activities are subject to control by many
paracrine growth factors, most notably by members of
the transforming growth factor β (TGFβ)/bone morpho-
genetic protein (BMP) superfamily. BMP-2 was first
noted in inducing ectopic bone formation when it was
implanted in muscles (Wozney et al., 1988). A large
body of evidence has now shown that different BMPs,
their membrane receptors, and their antagonists all
play prominent roles in controlling osteoblast differenti-
ation and deposition of bone ECM (Balemans and Van
Hul, 2002; Zhao et al., 2002; Wu et al., 2003). By antago-
nizing the inductive effect of BMP, TGFβ inhibits ex-
pression of Runx2 and osteocalcin (Alliston et al., 2001)
and blocks osteoblast differentiation (Maeda et al.,
2004). The intracellular signaling of TGFβ and BMP is
mediated primarily by Smad proteins (Massagué, 2000;
Derynck and Zhang 2003), which normally accumulate
in the cytoplasm but traverse into the nucleus when
they are phosphorylated by activated receptor serine/
threonine kinases. On several occasions, Smads are
found to interact with Runx2 to modulate the expres-
sion of bone ECM components (Ito and Miyazono,
2003). In addition to the Smad-mediated canonical sig-
naling pathway, TGFβ and BMP can also activate mito-
gen-activated protein kinases (MAPKs) such as JNK
and p38 MAPK (Engel et al., 1999; Yu et al., 2002; Bakin
et al., 2002; Itoh et al., 2003). These crosstalks are likely
to integrate the input from diverse paracrine signals to
allow for cooperative activation of gene expression by
Smads and MAPK downstream substrates c-Jun,
JunB, and ATFs (Zhang et al., 1998; Liberati et al., 1999;
Sano et al., 1999; Wong et al., 1999).
With the identification of Smad ubiquitin regulatory
factor (Smurf), a HECT domain ubiquitin ligase, the role
of ubiquitin/proteasome system in modulating TGFβ
and BMP signaling has received attention. Two highly
related Smurf genes exist in vertebrates: Smurf1 and
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102Smurf2 (Zhu et al., 1999; Lin et al., 2000; Kavsak et al., g
o2000; Zhang et al., 2001). Ectopic expression of Smurf1
in pluripotent mouse C2C12 myoblasts (Ying et al., 2
o2003) as well as in 2T3 osteoblast progenitor cells
(Zhao et al., 2004) prevents osteoblast differentiation. B
eBoth Smurf1 and Smurf2 have the ability to interact di-
rectly with Smad1 and Smad5 of the BMP pathway and g
bmediate their degradation. However, these two proteins
can act in another mechanistic mode to mediate ubiqu- c
mitination of either TGFβ or BMP type I receptors through
ligand-activated binding of inhibitory Smad6 or Smad7 b
pas intermediate (Kavsak et al., 2000; Ebisawa et al.,
2001; Murakami et al., 2003). Recent in vitro biochemi- s
cal studies also suggest that Smurf1 can target Runx2
and small GTPase RhoA for ubiquitination and degra- E
dation (Zhao et al., 2003; Wang et al. 2003). T
Here, we disrupted the mouse Smurf1 allele and a
found that Smurf1-deficient mice are perinatally normal d
but exhibit an age-dependent increase of bone mass o
due to enhanced osteoblast activity. Surprisingly, o
Smurf1 does not exert its control of osteoblast function a
through the Smad-dependent canonical TGFβ/BMP T
signaling; instead, it promotes ubiquitination and de- m
struction of MEKK2, an upstream kinase in the JNK sig- c
naling cascade. Our results thus reveal a novel aspect 2
of the molecular underpinning of osteoblast function v
and identify a physiological substrate of the Smurf1 b
ubiquitin E3 ligase. a
9
TResults
b
bIncreased Bone Mass in Smurf1-Deficient Mice
Mouse Smurf1 locus was disrupted through targeted t
ghomologous recombination (Figures 1A–1C). This ma-
nipulation was expected to generate a genetic null al- 2
slele, as it would give rise to a truncated protein product
that lacks the two highly conserved WW domains and c
athe HECT ubiquitin ligase domain (Figure 1B), which are
indispensable for Smurf function (Zhu et al., 1999; Lin p
bet al., 2000; Kavsak et al., 2000; Zhang et al., 2001).
Homozygous mutant (Smurf1−/−) mice were born at ex- T
cpected Mendelian ratio (see Table S1 in the Supple-
mental Data available with this article online), had a o
onormal life span, and were as fertile as their wild-type
littermates. At the molecular level, however, the mu- l
otated Smurf1 transcript appeared to be less stable than
its wild-type counterpart as it accumulated to a much c
Slower level in total cellular RNA in contrast to a marked
increase of the Smurf2 transcript (Figure 1D). Given the d
acrucial inductive role by the signaling output of TGFβ/
BMP, this compensatory increase of Smurf2 expression t
Swas likely to be causative to the seemingly normal em-
bryonic development of Smurf1−/− mice. Despite the b
lack of gross developmental abnormalities or health
problems of the newborns, complete necropsy and his- g
dtological examination of 20 Smurf1−/− mice between
ages 4 and 15 months revealed a thickening of diaphy- S
tsis in more than 75% of long bones from the cohort
(Figure 1E). No other significant alteration in skeletal t
imorphology was observed (data not shown). Measure-
ment of bone mineral density (BMD) showed that this w
qthickening represented a bone mass increase primarily
between the topographical sections 4 and 17 of the fe- p
murs (Figure 1F). Although newborn Smurf1−/− mice be-an with a normally mineralized skeleton, the increase
f BMD progressed with age, reaching 10%, 17%, and
0% more than that of control littermates by the ages
f 4, 9, and 14 months, respectively. Little difference of
MD was seen in metaphysis or epiphysis at the either
nd of femurs (Figure 1F, sections 1–4 and 17–20), re-
ions primarily consisting of trabecular bones. This
one mass increase is likely due to cell-autonomous
auses rather than alteration in the production of bone-
etabolizing hormones or a general endocrine distur-
ance, as no apparent change in the serum levels of
arathyroid hormone, calcium, or phosphorus was ob-
erved (data not shown).
nhanced Osteoblast Activity in Smurf1−/− Mice
o investigate the cellular basis of bone mass increase
ssociated with loss of Smurf1 function, we performed
etailed histomorphometric measurements in sections
f undecalcified tibiae that were collected at the ages
f 4 and 9 months. Similar to femurs, Smurf1−/− tibiae
lso exhibited a marked thickening of cortical bone.
he ratio of cortex width to total bone diameter at the
idpoint of tibiae, a two-dimensional approximation of
ortical bone volume, was about 20% higher (Figure
A, left panel). Likewise, the ratio of trabecular bone
olume to tissue volume, a surrogate measure of tra-
ecular bone mass, increased slightly at 4 months of
ge (13.13% versus 11.73%) but more dramatically at
months (4.54% versus 2.99%) (Figure 2A, right panel).
he hitherto-described bone mass increase could not
e attributed to the cartilage-dependent endochondral
one formation, as the length and the growth plate ana-
omic structure of Smurf1−/− long bones were indistin-
uishable from those of wild-type mice (Figures 1E and
B and data not shown). In contrast, change was ob-
erved neither in the number of multinucleated osteo-
lasts that were stained positive for tartrate-resistant
cid phosphatase (TRAP) (Figures 2B and 2C, left
anel) nor in the number of osteoblasts in 1% Toluidine
lue stained bone sections (Figure 2C, right panel).
hus, this ruled out an imbalance in osteoblast/osteo-
last differentiation, which would have altered the ratio
f the respective cell numbers as a likely cause of the
bserved bone mass increase. However, calcein double
abeling analysis, a histomorphometrical measurement
f osteoblast activity in vivo, revealed a significant in-
rease in bone formation rate associated with loss of
murf1 (Figures 2D and 2E) while urinary elimination of
eoxypyridinoline, a biochemical marker of osteoclast
ctivity, was normal (data not shown). Taken together,
hese results indicate that the bone mass increase in
murf1−/− mice likely emanates from an enhanced
one-forming activity of osteoblasts.
To ascertain that the expression pattern of Smurf
enes is compatible with a role in osteoblast, we con-
ucted in situ hybridization analyses in tibiae sections.
ignals of Smurf1 transcript were concentrated in os-
eoblasts and proliferative chondrocytes but not in os-
eoclasts (Figure 2F). Smurf2 transcript exhibited a sim-
lar cellular distribution, but its level in Smurf1−/− tibiae
as markedly increased (Figure 2F). Real-time RT-PCR
uantification of mRNA isolated from bone extracts or
urified osteoblasts confirmed the increase of Smurf2expression (Figure 2G). Apparently, the elevated Smurf2
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(A) Generation of Smurf1-deficient mice. Closed box, exon; shaded box, selective marker, pGKneo or pGKtk; N, NotI; X, XhoI; B, BamHI.
(B) Structural organization of Smurf1 protein. Sequence surrounding the acquired splicing junction between Exons 5 (upper case) and Exon
9 (lower case) was confirmed by sequencing the RT-PCR products in (D).
(C) (Upper panel) Southern blot analysis of the homologous recombination using the 5# external probe (shown in [A]). Wt, 11.5 kb; mutant,
13.5 kb. (Lower panel) PCR genotyping. Wt and mutated alleles yield 84 bp and 450 bp products, respectively.
(D) RT-PCR analyses of Smurf1 and Smurf2 expression using total RNA isolated from newborn wild-type and Smurf1−/− mice. For Smurf1
expression, a primer pair from E5 and E9 (arrows in [B]) was used. Amplification of Hprt was used as an internal control.
(E) Villanueva Goldner staining of plastic sections of tibiae from mice at age of 9 months. Scale bar, 0.4 mm. C, cortical bone; T, trabecular
bone.
(F) BMD measurement in 20 divisions from the proximal to distal femora of male mice at ages of 1, 4, 9, and 14 months. Wt: n = 4; Smurf1−/−:
n = 8 (1 month old), or n = 6 (4, 9, 14 month old). Statistical difference of Smurf1−/− mice from Wt mice was assessed by Student’s t test.
*p < 0.05, **p < 0.01.was not sufficient to completely compensate for the
loss of Smurf1 function that enhanced osteoblast ac-
tivity.
Smurf1 Negatively Regulates Osteoblast Function
and Response to BMP
A consequence of enhanced osteoblast activity would
be acceleration of bone ECM production. Real-time RT-
PCR analyses revealed that this indeed was the case.
The mRNA levels of α1 collagen type 1, α2 collagen
type 1, osteocalcin, and bone sialoprotein were all in-
creased in bone extracts of Smurf1−/− mice (Figure 3A).
In contrast, the mRNA level of Runx2, the early differen-
tiation marker of commitment to osteoblastic lineage,
was unchanged (Figure 3A). This observation was con-
sistent with the normal number of osteoblasts de-
scribed in above histomorphometric measurements
(Figure 2C).
To specifically address the impact of loss of Smurf1
on bone-forming activity of osteoblasts, we established
an osteoblast culture using cells isolated from calvaria
bones. In vitro differentiation of mesenchymal progeni-
tor cells or immature osteoblasts that are enriched in
this culture faithfully recapitulates the osteoblast matu-
ration process in expressing alkaline phosphatases
(ALP), depositing type I collagen to ECM, and forming
mineralized bone nodules (Bhargava et al., 1988). In
Smurf1−/− osteoblasts, although ALP activity was com-
parable to that of wild-type osteoblasts initially after
culturing ex vivo for 7 days, it became significantly
higher after 10 days (Figures 3B and 3C). Similarly,
production of collagen matrix (van Gieson staining) wasdramatically increased after 12 days (Figure 3C), and
more and bigger mineralized bone nodules (von Kossa
staining) appeared after 21 days (Figure 3C). Thus, dis-
ruption of Smurf1 clearly has an augmentative effect on
osteoblast activity, indicating that Smurf1 normally is a
negative regulator of osteoblast function.
Both TGFβ and BMP play important roles in osteo-
blast differentiation and function, and, as implicated by
previous in vitro studies, Smurf1 has the potential to
degrade the BMP pathway-specific Smads and BMP or
TGFβ type I receptors (Zhu et al., 1999; Ebisawa et al.,
2001; Murakami et al., 2003; Ying et al., 2003). We thus
examined the effect of TGFβ or BMP on osteoblastic
function in calvaria cell culture. At the seventh day of ex
vivo culturing, little ALP activity was detected without
ligand treatment (Figures 3B and 3D). In the presence
of BMP-2, however, ALP activity was induced in wild-
type cells at this early time point, but a much robust
induction was observed in Smurf1−/− cells (Figure 3D).
In the presence of TGFβ, which inhibits osteoblast dif-
ferentiation and function, the basal level of ALP activity
was suppressed, and, when added together with BMP-2,
TGFβ also suppressed the BMP-induced ALP activity
by more than 80% in both types of cells (Figure 3D).
These results indicate that Smurf1-deficient osteo-
blasts were sensitized to BMP signaling while probably
having a normal response to TGFβ.
Normal Smad-Dependent Responses
in Smurf1-Deficient Osteoblasts
To further delineate the effect of loss of Smurf1 on
TGFβ or BMP signaling in osteoblasts, we analyzed the
Cell
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(A) Bone morphometric analyses of 4- and 9-month-old male mice (n = 4). Ct.Wi/B. Dm, cortex bone width per bone diameter; BV/TV,
trabecular bone volume per tissue volume. Statistical difference between two mice groups was assessed by Student’s t test.
(B) TRAP staining of osteoclasts in proximal epiphysis of tibia from 4-month-old mice.
(C) Quantification of osteoclast (left) and osteoblast (right) cell numbers.
(D) Calcein-labeled mineralization fronts in tibiae cortex bone from 4-month-old mice by fluorescent micrography. Scale bar = 0.2 mm.
(E) Quantification of bone formation rate measured with calcein double-labeling.
(F) In situ hybridization analyses of Smurf1 and Smurf2 expression in tibia at the metaphysis (top panels) and near cortical bone (bottom
panels). (Middle panels) Insets of top panels at higher magnification. Sections were counterstained with nuclear fast red. PC, proliferative
chondrocytes; Obs, osteoblasts; Ocs, osteoclasts.
(G) Real-time RT-PCR measurement of Smurf2 transcript from lone bones or osteoblasts.signaling output of a number of pathway-specific tran- r
gscriptional reporters that were transfected into calvaria
cells. We began with (CAGA)12-luc, which can be acti- o
pvated only by TGFβ through its type I receptor (Dennler
et al., 1998), and BRE-luc, a BMP-specific transcription veporter driven by BMP-responsive elements of the Id1
ene (Korchynskyi and ten Dijke, 2002). While addition
f either TGFβ or BMP-2 stimulated their respective re-
orters, the extent to which these reporters were acti-
ated was independent of the genetic background of
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Smurf1−/− Mice and BMP Sensitivity of
Smurf1−/− Osteoblasts
(A) Real-time PCR of osteoblast marker
genes from long bone mRNA of 4-month-old
wild-type (open column) or Smurf1−/− mice
(closed column). Values are presented as rel-
ative expression.
(B) Time course of ALP activity in differenti-
ating calvaria cell culture.
(C) Calvaria-derived osteoblasts were dif-
ferentiated for 12 days in vitro and stained
for collagen matrix formation (van Gieson)
and ALP activity. Von Kossa staining for min-
eralized nodules was done after culturing for
21 days.
(D) ALP activity of calvaria-derived cells after
7 days of differentiation in the presence of
exogenous BMP-2 and/or TGFβ.the cells in which they were tested (Figure 4A). Western
blot analyses showed little difference in the levels of
total Smad2 and Smad3 (Figure 4B), Smad1 and Smad5,
and the BMP type IA and IB receptors (Figure 4C). Al-
though the BMP-2-mediated Smad1 and Smad5 phos- deficient osteoblasts are sensitized to BMP for con-
Figure 4. Normal Smad-Dependent TGFβ and BMP Response in Smurf1−/− Osteoblasts
(A) Smad-dependent TGFβ or BMP signaling in osteoblasts measured by (CAGA)12-Luc or BRE-luc transcription reporter assay.
(B) Western analyses of TGFβ-induced Smad2 phosphorylation and the steady-state levels of the endogenous Smad2 and Smad3.
(C) Western analyses of BMP-2-induced Smad1/5 phosphorylation and the steady-state levels of the endogenous total Smad1/5, BMP
receptors (BMPRIA and BMPRIB), and Runx2.
(D) Effect of loss of Smurf1 on transcription from the Runx2-dependent osteocalcin promoter (OC-Luc).
(E) Effect of loss of Smurf1 on transcription from 3TP-Lux. Open bar, wild-type; closed bar, Smurf1−/−.phorylation lasted longer than that of the TGFβ-medi-
ated Smad2 phosphorylation, no significant difference
was observed between wild-type and Smurf1−/− osteo-
blasts (Figures 4B and 4C). Thus, even though Smurf1-
Cell
106trolling bone-forming activity, the Smad-dependent c
mTGFβ and BMP signaling per se is not affected. Not-
withstanding, Smurf1 did display the ability to down- p
tregulate the activities of these pathway-specific re-
porters when it was overexpressed (Figure 4A), in s
Magreement with previous reports (Zhu et al., 1999; Ebi-
sawa et al., 2001; Murakami et al., 2003). d
hSurprisingly, when the signaling response was mea-
sured with a set of more complex transcriptional repor- p
oters—OC-luc for monitoring BMP response and 3TP-
lux for TGFβ response—a much potent transcriptional i
tactivation was now observed in Smurf1−/− cells (Figures
4D and 4E). The control elements of OC-luc reporter r
twere derived from the osteocalcin promoter (Ducy and
Karsenty, 1995), whose activation requires osteoblast- a
ispecific transcription factor Runx2 and is influenced by
interaction between Runx2 and other coactivators, in- t
2cluding Smads and AP-1 (Franceschi and Xiao, 2003;
Ito and Miyazono, 2003). Without culturing in differenti- A
bation medium or introduction of exogenous Runx2, OC-
luc remained silent (Figure 4D). In the presence of exog- i
tenous Runx2, however, OC-luc was activated by BMP
in both wild-type and Smurf1−/− cells, but the extent of i
Sactivation was much higher in Smurf1−/− cells (Figure
4D). Although it was reported that Smurf1 could cause p
Sdegradation of Runx2 (Zhao et al., 2003), and overex-
pression of Smurf1 did decrease the overall transcrip- t
ttion activity from this reporter (Figure 4D), the aug-
mented activation of OC-luc in Smurf1−/− cells could w
Rnot be accounted solely by such a mechanism because
the protein level of Runx2 was unchanged (Figure 4C). 5
tSimilarly, an enhancement of TGFβ-induced transcrip-
tion activation was observed in Smurf1−/− cells when i
Sassayed by 3TP-lux (Figure 4E), whose promoter con-
tains three tandem repeats of the AP-1 binding element c
aand a segment of the TGFβ-inducible PAI-1 promoter
(Wrana et al., 1992). Because the AP-1 family of tran- b
sscription factors can cooperate with Runx2 or Smad to
increase Runx2- or Smad-dependent transcription a
e(Zhang et al., 1998; Wong et al., 1999; Hess et al., 2001;
D’Alonzo et al., 2002), the above results suggest that a
tSmurf1 may regulate osteoblast function and response
to BMP by modulating AP-1 activity. t
o
Activation of JNK Kinase Cascade S
in Smurf1-Deficient Osteoblasts M
The overt increase of osteoblast activity in Smurf1−/− H
mice and the seeming lack of change in the Smad- c
dependent signaling prompted us to look beyond the t
orthodox TGFβ/BMP intracellular signaling pathway for S
physiological target of Smurf1 function. The crosstalks t
between TGFβ/BMP signaling and various MAP kinases f
are well substantiated (Massagué, 2000; Derynck and t
Zhang 2003). Two MAP kinases, JNK and p38 MAPK, w
which act upstream of the AP-1 family transcription a
factors, have recently been shown to play a role in con- o
trolling bone ECM production, expression of osteoblast i
specific markers, and other aspects of osteoblast func- a
tion (Guicheux et al., 2003). Indeed, Western blot analy- M
ses showed that, while JNK could become phosphory- a
lated in response to BMP in wild-type osteoblasts, it was S
Talready phosphorylated without the ligand in Smurf1−/−ells (Figure 5A). The level of total JNK, however, re-
ained constant (Figure 5A), suggesting that the ap-
earance of phosphorylated JNK was due to post-
ranslational activation. In contrast, little change was
een in the levels of either total or phosphorylated p38
APK (Figure 5A). Consequential to JNK activation,
ownstream JNK-dependent transcription was en-
anced in Smurf1−/− cells, as indicated by AP1-luc re-
orter assay (Figure 5B). In addition, the protein level
f one of JNK targets, JunB, but not c-Jun or JunD was
ncreased in Smurf1−/− osteoblasts (Figure 5C), al-
hough neither c-Jun nor JunB itself constitutes as di-
ect target for Smurf1 (Figure S1). Functional coopera-
ion between Smads and other families of transcription
ctivators, including members of the AP-1 or ATF fam-
ly, is a recurring theme in activation of TGFβ/BMP
arget genes (Massagué, 2000; Derynck and Zhang
003). Thus, the activation of JNK and its downstream
P-1 or ATF effectors may account for the enhanced
one-forming activity as well as the increased sensitiv-
ty to BMP signaling in Smurf1−/− osteoblasts. To test
his hypothesis, we applied SP600125, a JNK-specific
nhibitor, to the calvaria cell culture. Blocking JNK by
P600125 suppressed the accelerated bone ECM
roduction and reduced the augmented ALP activity in
murf1−/− osteoblasts to a level that was comparable
o that in wild-type cells (Figure 5D). This was specific
o the inhibition of JNK because treating calvaria cells
ith SB203580, a p38 MAPK inhibitor, or Y27632, a
ho-dependent kinase inhibitor, had little effect (Figure
D). Blocking JNK also specifically desensitized the os-
eoblasts to BMP signaling, as the amplitude of BMP-
nduced ALP activity was curtailed by the addition of
P600125 (Figure 5E). Based on the results above, we
onclude that activation of the JNK kinase cascade is
n essential molecular change that leads to enhanced
one-forming activity and sensitizes BMP response as-
ociated with the loss of Smurf1 function. Interestingly,
lthough blocking p38 MAPK by SB203580 had little
ffect on basal level of bone ECM production and ALP
ctivity (Figures 5D and 5E), it nevertheless dampened
he BMP-induced ALP activity (Figure 5E), suggesting
hat p38 MAPK may play a role in the BMP-stimulated
steoblast activity.
murf1 Physically Interacts with and Targets
EKK2 for Ubiquitination
aving established a requirement for the JNK kinase
ascade, we set out to identify a direct target of Smurf1
hat controls osteoblast activity and BMP response.
murfs are known to recognize a “PY” motif that has
he ability to interact with WW domains of the HECT
amily E3 ligases (Sudol and Hunter, 2000). No such mo-
if was present in JNK, nor did JNK interact physically
ith Smurf1 (data not shown). These preclude JNK itself
s a direct Smurf1 target. We then scanned the sequence
f several kinases that are known to act upstream of JNK,
ncluding MKK3, -4, -6, and -7; MEKK1, -2, -3, and -4;
nd TAK1 (Davis, 2000). Among these, only MEKK2 and
EKK3 contain a PY motif. Western blot showed that
slow-migrating band of MEKK2 accumulated in
murf1−/− but not wild-type osteoblasts (Figure 6A).
his slow-migrating band is likely to be the phosphory-
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107Figure 5. Elevated JNK Activity in Smurf1−/−
Osteoblasts
(A) Western analyses of JNK and p38 MAPK
phosphorylation in isolated osteoblasts. Where
indicated, BMP-2 was added at 100 ng/ml
for 30 min prior to sample preparation.
(B) JNK-dependent AP-1 transcription as
measured by AP-1-luc reporter. SRE-luc, a
control reporter containing the serum re-
sponse element.
(C) Western analyses of endogenous c-Jun,
JunB, and JunD expression.
(D) Blocking the augmented collagen matrix
production and ALP activity by JNK inhibitor
in Smurf1−/− osteoblasts. Experiments were
carried out as in Figure 3C except for the ad-
dition of SP600125, SB203580, or Y27632.
(E) ALP quantification in osteoblasts cultured
for 12 days. The relative activity was ex-
pressed as fold to the ALP activity of wild-
type osteoblasts in the absence of inhibitors
and BMP-2.lated MEKK2, because introduction of the wild-type but
not a kinase-deficient MEKK2 cDNA (Su et al., 2001)
into mouse embryonic fibroblasts (MEFs) gave rise to a
similar slow-migrating band, which could be collapsed
to the normal migrating band by λ-phosphatase treat-
ment (Figure 6B). In contrast to the accumulation of
phosphorylated MEKK2, no difference in the level of the
related MEKK3 was observed (Figure 6A). No discerni-
ble change was seen in two other kinases, MEKK1 and
TAK1, which were implicated previously in TGFβ/BMP
signaling (Brown et al., 1999; Yamaguchi et al., 1999)
(Figure 6A). Nor was the level of RhoA (Figure 6A), a
small GTPase that was recently reported as a target of
Smurf1 (Wang et al., 2003) and could function upstream
of JNK.
To investigate if MEKK2 accumulates in the absence
of Smurf1 due to impairment of protein turnover, we
measured the turnover rate of exogenous MEKK2 in
MEFs. Western analyses showed that the rate of
MEKK2 turnover was indeed impeded in Smurf1−/−
MEFs (Figure 6C). This was especially true to the phos-
phorylated MEKK2; however, the turnover rate of ki-
nase-deficient MEKK2(KM) was unaffected (Figure 6C).
Similar results were obtained with pulse-chase labeling
experiments. In wild-type MEFs, MEKK2 displayed a
half-life of less than 1 hr, which was prolonged to about
2 hr in Smurf1−/− MEFs, similar to that of MEKK2(KM)
(Figure 6D). Taken together, the above results suggest
that MEKK2 is a target of Smurf1.
To determine if Smurf1 specifically interacts with
MEKK2, we coexpressed MEKK2 with Smurf1, Smurf2,
or dominant-negative mutants carrying an inactivating
point mutation in their respective HECT E3 ligase do-
main in Smurf1−/− MEFs. In agreement with the protein
turnover studies, MEKK2 and its phosphorylated formceased to accumulate when it was coexpressed with
the wild-type Smurf1 (Figure 6E, lane 2) but accumu-
lated to high level with Smurf1(DN) (lane 3). Once again,
accumulation of the kinase-deficient MEKK2(KM) was
unaffected by Smurf1 or Smurf1(DN) (Figure 6E, lanes
6–8). Coexpression of Smurf2 or Smurf2(DN) had little
effect on MEKK2 (Figure 6E, lanes 4 and 5), indicating
that turnover of MEKK2 was specifically controlled by
Smurf1. Immunoprecipitation experiments showed that
Smurf1(DN) interacts strongly with the HA-tagged
MEKK2 (Figure 6E, lane 3) but weakly with MEKK2(KM)
(lane 7). Consistent with the resistance to Smurf2,
MEKK2 did not coprecipitate with Smurf2 (Figure 6E,
lanes 4 and 5). We did not detect wild-type Smurf1 in
the anti-HA-MEKK2 pellet (Figure 6E, lane 2), possibly
because MEKK2 was rapidly degraded once it was re-
cruited to Smurf1. To demonstrate the in vivo interac-
tion between these two proteins, we pretreated calvaria
cells with the proteasome inhibitors MG132 and
MG115. A slow-migrating phosphorylated MEKK2 ac-
cumulated under this condition in the otherwise wild-
type osteoblasts, and the endogenous Smurf1 was co-
precipitated with the accumulated MEKK2 (Figure 6F).
The hitherto described interaction appears to be of di-
rect nature, as it is corroborated in yeast two-hybrid
assay (Figure 6G) in which no homolog of TGFβ/BMP
receptors or Smads exists. Mapping studies showed
that MEKK2 specifically interacts with the two WW do-
mains of Smurf1 between residues 146 and 351 and
that this binding requires the PY motif of MEKK2 (Fig-
ure 6G).
To formally demonstrate that MEKK2 is a substrate of
Smurf1, we performed a series of ubiquitination assays.
First, in wild-type calvaria cells, polyubiquitinated MEKK2
accumulated to a higher level than in Smurf1−/− cells in
Cell
108Figure 6. Accumulation of Phosphorylated MEKK2 in Smurf1−/− Osteoblasts and Physical Interaction between Smurf1 and MEKK2
(A) Western analyses of MEKK2, MEKK3, MEKK1, TAK1, and RhoA in osteoblasts.
(B) Western analyses of HA-tagged MEKK2 or kinase-deficient MEKK2 (KM) after immunoprecipitation from transfected Smurf1−/− MEFs.
(C) Western analyses of HA-MEKK2 and HA-MEKK2(KM) in transfected MEFs at the indicated intervals following cycloheximide treatment.
(D) [35S]-methionine labeling and chase studies of MEKK2 and MEKK2 (KM) in wild-type Smurf1−/− MEFs. The amount of each labeled protein
was expressed as the percentage of that at the beginning of chase (time 0).
(E) Interaction between exogenous Smurfs and MEKK2 in Smurf1−/− MEFs. Expression of the HA-tagged MEKK2s and the Myc-tagged
Smurfs was shown in top and middle panel, respectively. Only Smurf1(DN) coimmunoprecipitated with the wild-type MEKK2 and weakly with
MEKK2(KM) (bottom panel, lanes 3 and 8).
(F) Interaction between endogenous Smurf1 and MEKK2. MEKK2 was precipitated from wild-type and Smurf1−/−osteoblasts that were pre-
treated with proteasome inhibitors and subjected to Western analysis with anti-Smurf1 antibody (top panel). The amount of total MEKK2 and
Smurf1 present in cell lysates was shown at two bottom panels.
(G) Requirements for direct interaction between Smurf1 and MEKK2 as revealed by yeast two-hybrid assays. Binding of the WW domains of
Smurf1 to Smad1 or Smad7 was included as positive controls.the presence of proteasome inhibitors (Figure 7A). Sec- t
pond, in transfected Smurf1−/− MEFs, we detected poly-
ubiquitinated MEKK2 only when it was coexpressed p
Ewith Smurf1 (Figure 7B). Accumulation of polyubiquiti-
nated MEKK2 was dependent on its intrinsic kinase ac- u
tivity and the functionality of Smurf1 HECT E3 ligase
(Figure 7B). Third, we reconstituted the ubiquitination of J
rMEKK2 in vitro using MEKK2 isolated from transfected
Hep3B cells, purified E1 and E2, and in vitro-translated e
tSmurf1. In this reconstituted system, only the wild-type
MEKK2 became polyubiquitinated when it was mixed f
2with Smurf1 but not a truncated Smurf1 lacking the
HECT domain (Figure 7C, lanes 2 and 1). The kinase- o
ldeficient MEKK2(KM) was refractory to Smurf1-medi-
ated ubiquitination (Figure 7C, lanes 5 and 6). Pretreat- M
ging the isolated MEKK2 with λ-phosphatase abolished
its ubiquitination (Figure 7C, lanes 3 and 4), suggestinghat Smurf1-mediated ubiquitination of MEKK2 requires
hosphorylation. Similar results were obtained using
urified recombinant GST-Smurf1 fusion protein from
. coli and FLAG-MEKK2 from Drosophila S2 cells (Fig-
re 7D).
Finally, we expressed constitutively active MEKK2 or
NK, or kinase-deficient MEKK2 in osteoblasts by ret-
ovirus-mediated transduction (Figures 7E and 7F), and
xamined the effect of the ectopic expression on os-
eoblast activity. MEKK2(CT), the constitutively active
orm containing only the kinase domain (Cheng et al.,
000), strongly activated JNK, as revealed by the ability
f JNK1 from the infected calvaria cells to phosphory-
ate GST-c-Jun in an in vitro kinase assay (Figure 7E).
EKK2(CT) also induced high levels of ALP and colla-
en matrix production in both wild-type and Smurf1−/−osteoblasts after they were put in differentiation me-
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109Figure 7. MEKK2 Is a Substrate of Smurf1-Mediated Ubiquitination and Activation of MEKK2-JNK Pathway Is Sufficient to Enhance Osteo-
blast Activity
(A) Ubiquitination of endogenous MEKK2 in osteoblasts. Polyubiquitinated MEKK2 was detected by anti-ubiquitin Western analysis after
precipitation of MEKK2 from cells that were pretreated with proteasome inhibitors.
(B) Smurf1 promotes MEKK2 ubiquitination. Ubiquitinated F-MEKK2 in Smurf1−/− MEFs was visualized by anti-HA-ubiquitin Western analysis
after anti-FLAG immunoprecipitation. Expression of Myc-tagged Smurfs is shown in bottom panel.
(C) In vitro polyubiquitination of MEKK2 by Smurf1 detected by anti-HA blot. HA-MEKK2 and HA-MEKK2(KM) were isolated by anti-HA
antibody from transfected Hep3B cells. Myc-tagged Smurf1 and Smurf1(HECT) were in vitro translated and are shown in the right panel.
(D) In vitro ubiquitination of MEKK2 by purified GST-Smurf1 detected by anti-ubiquitin blot. FLAG-MEKK2 purified from transfected Drosophila
S2 cells is shown at bottom panel.
(E) In vitro kinase assay of JNK1 after immunoprecipitation from osteoblasts expressing MEKK2 mutants. GST-c-Jun was used as the kinase
substrate and was analyzed by anti-p-c-Jun blot. Total JNK1, HA-MEKK2(CT), and MEKK2(KM) are shown below.
(F) Western analyses of phosphorylated JNK in osteoblasts expressing HA-JNKK2-JNK1, which does not affect endogenous JNK activity.
Arrows, endogenous p-JNK1/2; arrowhead, p-JNKK2-JNK1 fusion.
(G) Ectopic expression of activated MEKK2 and JNK1 is sufficient to enhance osteoblast activity. Staining for ALP activity and collagen matrix
was carried out after incubating in differentiation medium for 16 days.
(H) ALP quantification of cells in (G) after differentiation for 12 days.dium (Figures 7G and 7H). Similarly, high levels of ALP
activity and collagen matrix production were induced
by JNKK2-JNK1, the constitutively active fusion protein
(Zheng et al., 1999) (Figures 7G and 7H). However, the
kinase-deficient MEKK2(KM) reduced the production of
ALP and collagen matrix in Smurf1−/− cells while having
little effect in wild-type osteoblasts (Figures 7G and
7H). We therefore conclude that MEKK2 is a bona fide
substrate of Smurf1 and activation of the MEKK2-JNKsignaling cascade in Smurf1−/− mice is sufficient to en-
hance osteoblast activity.
Discussion
In this study, we have uncovered a novel aspect of the
molecular underpinning of the bone homeostasis
through target inactivation of the mouse Smurf1 locus
and showed that loss of Smurf1 results in accumulation
Cell
110of phosphorylated MEKK2 and activation of the down- o
rstream JNK kinase cascade, which has the tenacity to
mobilize the AP-1/ATF family of transcription factors to g
fregulate osteoblast activity.
f
Smurf1 as a Negative Regulator of BMP Signaling
Biochemical interaction and functional studies have un- A
Scovered a long list of Smurf targets including Smad1/5,
Smad2, Smad6/7, and type I receptors of both TGFβ I
tand BMP pathways. However, despite intense scrutiny
through the use of transcription reporters and direct M
dprotein analyses, no indication of Smurf1 affecting the
Smad-dependent BMP/TGFβ signaling was found. It is f
Apossible that Smurf1 normally serves a very restricted
role in clamping down BMP signaling regardless of its a
Hother potentials. Alternatively, Smurf1 could have over-
lapping functions with Smurf2, which also has the abil- t
mity to degrade R-Smads or type I receptors. The latter
notion was corroborated by the 2-fold increase of a
ASmurf2 transcripts in Smurf1−/− mice. Indeed, our pre-
liminary analysis showed that the compounded Smurf1 J
cand Smurf2 doubly deficient embryos die prior to E9.5
(M.Y. and Y.E.Z., unpublished data), underscoring the n
acritical requirement of a common Smurf function during
embryogenesis. This embryonic lethality could be t
bbrought about by deregulated activation of Smads or
TGFβ/BMP type I receptors, as previous in vitro studies f
cwould suggest. The final depiction of Smurf1 physio-
logical function thus will be multifaceted, with specific t
Afunction in a given tissue mediated by a specialized
biochemical mechanism. c
t
WSmurf1 as a Negative Regulator
nof Osteoblast Function
tThe role of Smurf1 in osteoblasts was implicated pre-
Eviously in studies employing in vitro differentiation of
C2C12 myoblasts or 2T3 osteoblasts and transgenic
mice carrying a Smurf1 transgene driven by a type I M
Fcollagen promoter (Ying et al., 2003, Zhao et al., 2004).
The outcomes of these gain-of-function perturbations, s
(however, were quite different from the current loss-
of-function study. When ectopically expressed, Smurf1 (
dinteracts with and directs ubiquitin/proteasome-medi-
ated degradation of BMP pathway-specific Smads and/ S
aor Runx2 in osteoblast progenitor cells and reduces
both the number and proliferative potential of mature S
tosteoblasts in the transgenic mice. As such, it affects
the commitment of osteoblast precursors during early d
Mstage of osteoblast differentiation rather than bone-
forming activities of mature osteoblasts. These mecha- S
nnisms could operate in cells upon overexpression of
Smurf1 but may not do so obligatorily in its physiologi- t
pcal function.
It is unlikely that Smurf1 plays an indispensable role o
sin early commitment of osteoblast cell lineage because
the number of mature osteoblasts remains the same in m
dSmurf1−/− mice as in wild-type littermates (Figure 2C).
Studies of molecular markers seem to corroborate this t
pnotion, as no change was detected in the level of Runx2
expression, whereas expression of α1 collagen type 1, s
lα2 collagen type 1, osteocalcin, and bone sialoprotein,
all of which are markers of late-stage osteoblast matu- M
oration and function, was increased (Figure 3A). Thus,ur results indicate Smurf1 is a physiological negative
egulator of osteoblast function and place it in the same
roup of genes as ATF4 and Fra-1, which are required
or maintaining normal osteoblasts physiology and
unction (Eferl et al., 2004; Yang et al., 2004).
ctivation of MEKK2-JNK Kinase Cascade
ensitizes Osteoblasts to BMP Signaling
t is increasingly appreciated that TGFβ/BMP signals
hrough Smads and Smad-independent JNK or p38
APK kinases that play an important role in osteoblast
ifferentiation and function. The JNK downstream ef-
ector AP-1 regulates osteoblast biology by binding to
P-1 elements in osteoblast-specific gene promoters
nd by interaction with Runx2 (D’Alonzo et al., 2002;
ess et al., 2001). This paradigm is exemplified in the
ranscription of osteocalcin, the best-characterized
arker of osteoblast maturation, which is controlled by
t least three cis-acting elements: OSE1, OSE2, and
P-1 sites that are recognized by Runx2, ATF4, and
un/Fos, respectively (Ducy and Karsenty, 1995; Fran-
eschi and Xiao, 2003; Yang et al., 2004). Mice engi-
eered to lack JunB or Fra-1 selectively in bone cells
re osteopenic due to defects in osteoblast differentia-
ion and proliferation (Kenner et al., 2004) or reduced
one ECM production (Eferl et al., 2004). The current
inding extends the above observations by revealing a
ausal relationship between heightened osteoblast ac-
ivity and elevated JNK in Smurf1−/− osteoblasts. As
P-1/ATF factors are capable of interacting synergisti-
ally with Smads in controlling TGFβ and BMP-induced
ranscription (Zhang et al., 1998; Sano et al., 1999;
ong et al., 1999), one could speculate that Smurf1
ormally functions to keep the MEKK2-JNK pathway of
he Smad-independent arm from overactivating bone
CM production as the consequence of BMP signaling.
EKK2 Is a Substrate of Smurf1 E3 Ubiquitin Ligase
our lines of evidence from the present study directly
upport MEKK2 as a physiological substrate of Smurf1:
1) Smurf1 forms direct physical contact with MEKK2,
2) the interaction depends on the integrity of the “WW”
omains of Smurf1 and the PY motif of MEKK2, (3)
murf1 promotes MEKK2 ubiquitination both in vivo
nd in a reconstituted in vitro system, and (4) loss of
murf1 impedes MEKK2 turnover. The interaction be-
ween Smurf1 and MEKK2 requires a functional kinase
omain (Figure 6E), which often autophosphorylates.
oreover, phosphorylated MEKK2 accumulates in
murf1−/− cells (Figure 6A) and is preferentially ubiquiti-
ated by Smurf1 (Figures 7A–7D). These data suggest
hat the interaction between MEKK2 and Smurf1 is
hosphorylation dependent. Previously, WW domains
f Pin1, a peptidyl-prolyl isomerase, were shown to
pecifically bind to phosphoSer-Pro or phosphoThr-Pro
otifs (Lu et al., 1999). However, phosphorylation-
ependent binding is not known for WW domains of
he HECT family E3 ligases. It is not clear at present if
hosphorylated residues surrounding the PY motif con-
titute part of the binding requirement or if phosphory-
ation per se causes a conformational change in
EKK2 that exposes the PY motif to the WW domains
f Smurf1. Regardless of which mechanism, our data
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111indicate that phosphorylation is an obligatory step in
substrate recognition by Smurf1, suggesting a possible
way of controlling Smurf1-mediated ubiquitination.
Moreover, these data also provide the first example of
a MAPKKK that is targeted by a HECT family E3 ligase
for ubiquitin-mediated degradation.
The mechanism by which MEKK2 is activated in
Smurf1−/− osteoblasts is not clear, and, for that matter,
nor is it clear how MEKKs are activated in general. Nev-
ertheless, the fact that Smurf1−/− mice mature to adult-
hood with normal stature indicates that Smurf1 is not
essential for maintaining skeletal integrity; this may
have implication in targeting Smurf1 as a therapeutic
strategy for treating age-related bone loss such as os-
teoporosis.
Experimental Procedures
Bone Morphological and Histological Analysis
BMD was determined using a dual energy X-ray absorptiometry
apparatus (DCS-600R, Aloka, Japan). For in vivo fluorescent label-
ing, intraperitoneal injections of calcein (20 mg/kg body weight)
were twice administrated to mice with a 7 day interval. Tibiae dis-
sected at day 10 were fixed in 70% ethanol and embedded in gly-
colmethacrylate without decalcification, and longitudinal serial
sections were prepared. Unstained sections were visualized by flu-
orescence microscopy, and the ratio of mineralized surface to bone
surface and mineral appositional rate were measured to calculate
bone formation rate. Bone sections stained with Villanueva Goldner
method or 1% Toluidine blue were used to discriminate between
mineralized and unmineralized bone and to identify cellular compo-
nents. Similar sections were used for staining TRAP (specific for
osteoclasts) with leukocyte acid phosphatase kit (Sigma). The
numbers of osteoblast and osteoclast were quantified 0.2–4 mm
from growth plates in bone marrow cavity and endosteum. Trabec-
ular bone and cortex bone parameters were measured in bone mar-
row cavity 0.2–2 mm from growth plates or at the midpoint of tibiae,
respectively. Nomenclature, symbols, and units used hereof are
those according to field standard (Parfitt et al., 1987).
Cell Culture, Protein Analysis, and Pulse Labeling
Primary calvaria cells isolated from 2- to 4-daya-old mice (Ducy et
al., 1999; Zhao et al., 2002) were cultured in 24-well plates in
α-MEM plus 10% FBS. Two days after confluence, differentiation
was induced with addition of 100 g/ml ascorbic acid and 5 mM
β-glycerophosphate in the absence or presence of 100 ng/ml
BMP-2 or 5 ng/ml TGFβ. Histochemical staining was performed
using van Gieson and von Kossa method (Bhargava et al., 1988).
ALP staining and quantification were described (Ying et al., 2003).
SP600125, SB203580, and Y27632 (Calbiochem) were used at 10
M, 5 M, and 10 M, respectively. MEFs were derived from E14.5
embryos (Hogan et al., 1994).
MSCV-derived retroviral vector (Clontech) was used for express-
ing HA-tagged MEKK2(CT), MEKK2(KM), and JNKK2-JNK1. Pri-
mary calvaria cells were infected within two passages. Two days
after infection, puromycin (2.5 g/ml) was added for 3 days, and
the selected cells were then pooled and plated in 24-well plates for
differentiation analysis.
For protein analysis, cells were lyzed in 10 mM HEPES (pH 7.9)
containing 300 mM NaCl, 0.1 mM EGTA, 20% glycerol, 0.2% NP-
40, and protease inhibitors or in RIPA buffer. In cases of protea-
some inhibitor treatment, cells at 95% confluency were incubated
with MG132 and MG115 at 25 M each for 12–14 hr. For pulse-
chase labeling experiment, MEFs were transfected with 2 g of
indicated cDNA plasmids in two 60 mm plates, replated into five
wells of a 6-well plate, and labeled with 35S-pro-mix (NEN) (Zhang
et al., 2001).
Transcription Reporter Assays
Transcription reporter assays in osteoblast cells were performed in
12-well plates by transfecting 0.25 g of testing vectors and 0.2 gof pRL-TK (Promega) control vector per well. Luciferase activity
was determined after treating with BMP-2 (200 ng/ml) or TGFβ (5
ng/ml) for 18–20 hr. Results were obtained from at least two inde-
pendent experiments using cells isolated from different mice with
duplicate samples for each data point.
In Vitro Ubiquitination Assay
HA-tagged MEKK2 or MEKK2 (KM) or FLAG-tagged MEKK2 was
purified by immunoprecipitation from lysates of transfected Hep3B
cells (ATCC) or Drosophila S2 cells (Invitrogen), respectively. Iso-
lated MEKK2 were divided into two equal aliquots, one of which
was subjected to λ-phosphatase treatment (New England Biolabs).
In vitro ubiquitination was carried out in 30 l 50 mM HEPES-HCl
(pH 7.6), 0.7 g of E1, 1 g of recombinant Ubc-H5c, 15 g ubiqui-
tin, ATP regeneration system, and MG132 (5 M) (all from Boston
Biochem), and either in vitro-translated Smurf1 or Smurf1 (HECT)
or 2 g GST or GST-Smurf1 fusion protein purified from E. coli was
added. The reaction mixture was incubated at 25°C for 60 min be-
fore termination with SDS-sample buffer.
Creation of Smurf1−/− mice, RT-PCR, In Situ Analysis, Antibodies,
Plasmids, and Yeast Two-Hybrid Assay
See Supplemental Data.
Supplemental Data
Supplemental Data include three figures, two tables, Supplemental
Experimental Procedures, and Supplemental References and can be
found with this article online at http://www.cell.com/cgi/content/full/
121/1/101/DC1/.
Acknowledgments
We are in debt to Drs. B. Su, A. Lin, P. ten Dijke, C-H. Heldin, G.
Karsenty, T. Alliston, and K. Miyazono for various plasmid and anti-
body reagents; V. Barr for assistance with microscope and com-
puter software; and D. Smith for pathology service. We also thank
Dr. L. Samelson for critically reading the manuscript. M.Y. is a fellow
of Japan Society for the Promotion of Science.
Received: July 9, 2004
Revised: November 24, 2004
Accepted: January 20, 2005
Published: April 7, 2005
References
Alliston, T., Choy, L., Ducy, P., Karsenty, G., and Derynck, R. (2001).
TGF-β-induced repression of CBFA1 by Smad3 decreases cbfa1
and osteocalcin expression and inhibits osteoblast differentiation.
EMBO J. 20, 2254–2272.
Bakin, A.V., Rinehart, C., Tomlinson, A.K., and Arteaga, C.L. (2002).
p38 mitogen-activated protein kinase is required for TGFβ-medi-
ated fibroblastic transdifferentiation and cell migration. J. Cell Sci.
115, 3193–3206.
Balemans, W., and Van Hul, W. (2002). Extracellular regulation of
BMP signaling in vertebrates: a cocktail of modulators. Dev. Biol.
250, 231–250.
Bhargava, U., Bar-Lev, M., Bellows, C.G., and Aubin, J.E. (1988).
Ultrastructural analysis of bone nodules formed in vitro by isolated
fetal rat calvaria cells. Bone 9, 155–163.
Brown, J.D., DiChiara, M.R., Anderson, K.R., Gimbrone, M.A., Jr.,
and Topper, J.N. (1999). MEKK-1, a component of the stress
(stress-activated protein kinase/c-Jun N-terminal kinase) pathway,
can selectively activate Smad2-mediated transcriptional activation
in endothelial cells. J. Biol. Chem. 274, 8797–8805.
Cheng, J., Yang, J., Xia, Y., Karin, M., and Su, B. (2000). Synergistic
interaction of MEK kinase 2, c-Jun N-terminal kinase (JNK) kinase
2, and JNK1 results in efficient and specific JNK1 activation. Mol.
Cell. Biol. 20, 2334–2342.
D’Alonzo, R.C., Selvamurugan, N., Karsenty, G., and Partridge, N.C.
Cell
112(2002). Physical interaction of the activator protein-1 factors c-Fos L
gand c-Jun with Cbfa1 for collagenase-3 promoter activation. J.
Biol. Chem. 277, 816–822. t
SDavis, R.J. (2000). Signal transduction by the JNK group of MAP
kinases. Cell 103, 239–252. L
lDennler, S., Itoh, S., Vivien, D., ten Dijke, P., Huet, S., and Gauthier,
tJ.M. (1998). Direct binding of Smad3 and Smad4 to critical TGFβ-
3inducible elements in the promoter of human plasminogen activa-
tor inhibitor-type 1 gene. EMBO J. 17, 3091–3100. L
dDerynck, R., and Zhang, Y.E. (2003). Smad-dependent and Smad-
uindependent pathways in TGF-β family signalling. Nature 425,
577–584. M
KDucy, P., and Karsenty, G. (1995). Two distinct osteoblast-specific
ocis-acting elements control expression of a mouse osteocalcin
gene. Mol. Cell. Biol. 15, 1858–1869. M
CDucy, P., Starbuck, M., Priemel, M., Shen, J., Pinero, G., Geoffroy,
V., Amling, M., and Karsenty, G. (1999). A Cbfa1-dependent genetic M
Tpathway controls bone formation beyond embryonic development.
Genes Dev. 13, 1025–1036. n
2Ebisawa, T., Fukuchi, M., Murakami, G., Chiba, T., Tanaka, K., Ima-
mura, T., and Miyazono, K. (2001). Smurf1 interacts with trans- P
Mforming growth factor-β type I receptor through Smad7 and in-
duces receptor degradation. J. Biol. Chem. 276, 12477–12480. m
BEferl, R., Hoebertz, A., Schilling, A.F., Rath, M., Karreth, F., Kenner,
L., Amling, M., and Wagner, E.F. (2004). The Fos-related antigen S
TFra-1 is an activator of bone matrix formation. EMBO J. 23, 2789–
2799. a
BEngel, M.E., McDonnell, M.A., Law, B.K., and Moses, H.L. (1999).
Interdependent SMAD and JNK signaling in transforming growth S
ffactor-β-mediated transcription. J. Biol. Chem. 274, 37413–37420.
eFranceschi, R.T., and Xiao, G. (2003). Regulation of the osteoblast-
specific transcription factor, Runx2: responsiveness to multiple sig- S
Cnal transduction pathways. J. Cell. Biochem. 88, 446–454.
Guicheux, J., Lemonnier, J., Ghayor, C., Suzuki, A., Palmer, G., and W
ECaverzasio, J. (2003). Activation of p38 mitogen-activated protein
kinase and c-Jun-NH2-terminal kinase by BMP-2 and their implica- i
Stion in the stimulation of osteoblastic cell differentiation. J. Bone
Miner. Res. 18, 2060–2068. W
eHess, J., Porte, D., Munz, C., and Angel, P. (2001). AP-1 and Cbfa/
runt physically interact and regulate parathyroid hormone-depen- A
pdent MMP13 expression in osteoblasts through a new osteoblast-
specific element 2/AP-1 composite element. J. Biol. Chem. 276, 1
20029–20038. W
MHogan, B., Beddington, R., Costantini, F., and Lacy, E. (1994). Ma-
nipulating the Mouse Embryos: A Laboratory Manual, Second Edi- o
1tion (Cold Spring Harbor, New York: Cold Spring Harbor Labora-
tory Press). W
MIto, Y., and Miyazono, K. (2003). RUNX transcription factors as key
targets of TGF-β superfamily signaling. Curr. Opin. Genet. Dev. 13, h
43–47. W
mItoh, S., Thorikay, M., Kowanetz, M., Moustakas, A., Itoh, F., Heldin,
C.-H., and ten Dijke, P. (2003). Elucidation of Smad requirement in p
stransforming growth factor-β type I receptor-induced responses. J.
Biol. Chem. 278, 3751–3761. 1
YKarsenty, G., and Wagner, E.F. (2002). Reaching a genetic and mo-
lecular understanding of skeletal development. Dev. Cell 2, 389– I
(406.
fKavsak, P., Rasmussen, R.K., Causing, C.G., Bonni, S., Zhu, H.,
wThomsen, G.H., and Wrana, J.L. (2000). Smad7 binds to Smurf2
to form an E3 ubiquitin ligase that targets the TGFβ receptor for Y
Sdegradation. Mol. Cell 6, 1365–1375.
eKenner, L., Hoebertz, A., Beil, T., Keon, N., Karreth, F., Eferl, R.,
oScheuch, H., Szremska, A., Amling, M., Schorpp-Kistner, M., et al.
1(2004). Mice lacking JunB are osteopenic due to cell-autonomous
osteoblast and osteoclast defects. J. Cell Biol. 164, 613–623. Y
mKorchynskyi, O., and ten Dijke, P. (2002). Identification and func-
ptional characterization of distinct critically important bone morpho-
dgenetic protein-specific response elements in the Id1 promoter. J.
Biol. Chem. 277, 4883–4891. Yiberati, N.T., Datto, M.B., Frederick, J.P., Shen, X., Wong, C., Rou-
ier-Chapman, E.M., and Wang, X.-F. (1999). Smads bind directly
o the Jun family of AP-1 transcription factors. Proc. Natl. Acad.
ci. USA 96, 4844–4849.
in, X., Liang, M., and Feng, X.H. (2000). Smurf2 is a ubiquitin E3
igase mediating proteasome-dependent degradation of Smad2 in
ransforming growth factor-β signaling. J. Biol. Chem. 275, 36818–
6822.
u, P.J., Zhou, X.Z., Shen, M., and Lu, K.P. (1999). Function of WW
omains as phosphoserine- or phosphothreonine-binding mod-
les. Science 283, 1325–1328.
aeda, S., Hayashi, M., Komiya, S., Imamura, T., and Miyazono,
. (2004). Endogenous TGF-β signaling suppresses maturation of
steoblastic mesenchymal cells. EMBO J. 23, 552–563.
assagué, J. (2000). How cells read TGF-β signals. Nat. Rev. Mol.
ell Biol. 1, 169–178.
urakami, G., Watabe, T., Takaoka, K., Miyazono, K., and Imamura,
. (2003). Cooperative inhibition of bone morphogenetic protein sig-
aling by Smurf1 and inhibitory Smads. Mol. Biol. Cell 14, 2809–
817.
arfitt, A.M., Drezner, M.K., Glorieux, F.H., Kanis, J.A., Malluche, H.,
eunier, P.J., Ott, S.M., and Recker, R. (1987). Bone histomorpho-
etry: standardization of nomenclature, symbols, and units. J.
one Miner. Res. 2, 595–610.
ano, Y., Harada, J., Tashiro, S., Gotoh-Mandeville, R., Maekawa,
., and Ishii, S. (1999). ATF-2 is a common nuclear target of Smad
nd TAK1 pathways in transforming growth factor-β signaling. J.
iol. Chem. 274, 27161–27167.
u, B., Cheng, J., Yang, J., and Guo, Z. (2001). MEKK2 is required
or T-cell receptor signals in JNK activation and interleukin-2 gene
xpression. J. Biol. Chem. 276, 14784–14790.
udol, M., and Hunter, T. (2000). NeW wrinkles for an old domain.
ell 103, 1001–1004.
ang, H.R., Zhang, Y., Ozdamar, B., Ogunjimi, A.A., Alexandrova,
., Thomsen, G.H., and Wrana, J.L. (2003). Regulation of cell polar-
ty and protrusion formation by targeting RhoA for degradation.
cience 302, 1775–1779.
ong, C., Rougier-Chapman, E.M., Frederick, J.P., Datto, M.B., Lib-
rati, N.T., Li, J.M., and Wang, X.-F. (1999). Smad3-Smad4 and
P-1 complexes synergize in transcriptional activation of the c-Jun
romoter by transforming growth factor beta. Mol. Cell. Biol. 19,
821–1830.
ozney, J.M., Rosen, V., Celeste, A.J., Mitsock, L.M., Whitters,
.J., Kriz, R., Hewick, R., and Wang, E.A. (1988). Novel regulators
f bone formation: molecular clones and activities. Science 242,
528–1534.
rana, J.L., Attisano, L., Carcamo, J., Zentella, A., Doody, J., Laiho,
., Wang, X.-F., and Massagué, J. (1992). TGFβ signals through a
eteromeric protein kinase receptor complex. Cell 71, 1003–1014.
u, X.B., Li, Y., Schneider, A., Yu, W., Rajendren, G., Iqbal, J., Ya-
amoto, M., Alam, M., Brunet, L.J., Blair, H.C., et al. (2003). Im-
aired osteoblastic differentiation, reduced bone formation, and
evere osteoporosis in noggin-overexpressing mice. J. Clin. Invest.
12, 924–934.
amaguchi, K., Nagai, S., Ninomiya-Tsuji, J., Nishita, M., Tamai, K.,
rie, K., Ueno, N., Nishida, E., Shibuya, H., and Matsumoto, K.
1999). XIAP, a cellular member of the inhibitor of apoptosis protein
amily, links the receptors to TAB1–TAK1 in the BMP signaling path-
ay. EMBO J. 18, 179–187.
ang, X., Matsuda, K., Bialek, P., Jacquot, S., Masuoka, H.C.,
chinke, T., Li, L., Brancorsini, S., Sassone-Corsi, P., Townes, T.M.,
t al. (2004). ATF4 is a substrate of RSK2 and an essential regulator
f osteoblast biology: implication for Coffin-Lowry Syndrome. Cell
17, 387–398.
ing, S.X., Hussain, Z.J., and Zhang, Y.E. (2003). Smurf1 facilitates
yogenic differentiation and antagonizes the bone morphogenetic
rotein-2-induced osteoblast conversion by targeting Smad5 for
egradation. J. Biol. Chem. 278, 39029–39036.
u, L., Hebert, M.C., and Zhang, Y.E. (2002). TGF-β receptor-acti-
Smurf1 Modulates Osteoblast Activity through MEKK2
113vated p38 MAP kinase mediates Smad-independent TGF-β re-
sponses. EMBO J. 21, 3749–3759.
Zhang, Y., Feng, X.-H., and Derynck, R. (1998). Smad3 and Smad4
cooperate with c-Jun/c-Fos to mediate TGF-β-induced transcrip-
tion. Nature 394, 909–913.
Zhang, Y., Chang, C., Gehling, D.J., Hemmati-Brivanlou, A., and
Derynck, R. (2001). Regulation of Smad degradation and activity
by Smurf2, an E3 ubiquitin ligase. Proc. Natl. Acad. Sci. USA 98,
974–979.
Zhao, M., Harris, S.E., Horn, D., Geng, Z., Nishimura, R., Mundy,
G.R., and Chen, D. (2002). Bone morphogenetic protein receptor
signaling is necessary for normal murine postnatal bone formation.
J. Cell Biol. 157, 1049–1060.
Zhao, M., Qiao, M., Oyajobi, B.O., Mundy, G.R., and Chen, D.
(2003). E3 ubiquitin ligase Smurf1 mediates core-binding factor al-
pha1/Runx2 degradation and plays a specific role in osteoblast dif-
ferentiation. J. Biol. Chem. 278, 27939–27944.
Zhao, M., Qiao, M., Harris, S.E., Oyajobi, B.O., Mundy, G.R., and
Chen, D. (2004). Smurf1 inhibits osteoblast differentiation and bone
formation in vitro and in vivo. J. Biol. Chem. 279, 12854–12859.
Zheng, C., Xiang, J., Hunter, T., and Lin, A. (1999). The JNKK2–JNK1
fusion protein acts as a constitutively active c-Jun kinase that stim-
ulates c-Jun transcription activity. J. Biol. Chem. 274, 28966–28971.
Zhu, H., Kavsak, P., Abdollah, S., Wrana, J.L., and Thomsen, G.H.
(1999). A SMAD ubiquitin ligase targets the BMP pathway and af-
fects embryonic pattern formation. Nature 400, 687–693.
